O	0	13	Methodologies	Methodology	NNS	B-NP
O	14	17	for	for	IN	B-PP
O	18	27	measuring	measure	VBG	B-VP
O	28	38	carcinogen	carcinogen	NN	B-NP
O	39	46	adducts	adduct	NNS	I-NP
O	47	49	in	in	IN	B-PP
O	50	56	humans	human	NNS	B-NP
O	56	57	.	.	.	O

O	58	60	In	In	IN	B-PP
O	61	68	summary	summary	NN	B-NP
O	68	69	,	,	,	O
O	70	78	although	although	IN	B-SBAR
O	79	83	some	some	DT	B-NP
O	84	86	of	of	IN	B-PP
O	87	90	the	the	DT	B-NP
O	91	95	more	more	RBR	I-NP
O	96	106	optimistic	optimistic	JJ	I-NP
O	107	118	aspirations	aspiration	NNS	I-NP
O	119	122	for	for	IN	B-PP
O	123	128	human	human	JJ	B-NP
O	129	142	biomonitoring	biomonitoring	NN	I-NP
O	143	150	studies	study	NNS	I-NP
O	151	160	envisaged	envisage	VBD	B-VP
O	161	162	a	a	DT	B-NP
O	163	169	decade	decade	NN	I-NP
O	170	173	ago	ago	RB	B-ADVP
O	174	178	have	have	VBP	B-VP
O	179	182	not	not	RB	I-VP
O	183	187	been	be	VBN	I-VP
O	188	196	realized	realize	VBN	I-VP
O	197	201	thus	thus	RB	B-ADVP
O	202	205	far	far	RB	I-ADVP
O	205	206	,	,	,	O
O	207	211	some	some	DT	B-NP
O	212	224	considerable	considerable	JJ	I-NP
O	225	233	advances	advance	NNS	I-NP
O	234	238	have	have	VBP	B-VP
O	239	243	been	be	VBN	I-VP
O	244	248	made	make	VBN	I-VP
O	248	249	.	.	.	O

O	250	253	The	The	DT	B-NP
O	254	262	examples	example	NNS	I-NP
O	263	268	cited	cite	VBN	B-VP
O	269	274	above	above	IN	B-ADVP
O	275	283	indicate	indicate	VBP	B-VP
O	284	288	that	that	IN	B-SBAR
O	289	292	the	the	DT	B-NP
O	293	304	feasibility	feasibility	NN	I-NP
O	305	307	of	of	IN	B-PP
O	308	321	biomonitoring	biomonitoring	NN	B-NP
O	322	325	has	have	VBZ	B-VP
O	326	330	been	be	VBN	I-VP
O	331	338	clearly	clearly	RB	I-VP
O	339	350	established	establish	VBN	I-VP
O	350	351	.	.	.	O

O	352	354	In	In	IN	B-PP
O	355	363	addition	addition	NN	B-NP
O	363	364	,	,	,	O
O	365	369	they	they	PRP	B-NP
O	370	381	demonstrate	demonstrate	VBP	B-VP
O	382	385	the	the	DT	B-NP
O	386	390	need	need	NN	I-NP
O	391	394	for	for	IN	B-PP
O	395	406	preliminary	preliminary	JJ	B-NP
O	407	416	biomarker	biomarker	NN	I-NP
O	417	424	testing	testing	NN	I-NP
O	425	428	and	and	CC	I-NP
O	429	439	validation	validation	NN	I-NP
O	440	447	through	through	IN	B-PP
O	448	460	transitional	transitional	JJ	B-NP
O	461	468	studies	study	NNS	I-NP
O	469	474	prior	prior	RB	B-ADVP
O	475	477	to	to	TO	B-PP
O	478	483	their	their	PRP$	B-NP
O	484	489	field	field	NN	I-NP
O	490	501	application	application	NN	I-NP
O	501	502	.	.	.	O

O	503	505	In	In	IN	B-PP
O	506	509	the	the	DT	B-NP
O	510	514	next	next	JJ	I-NP
O	515	521	decade	decade	NN	I-NP
O	522	524	of	of	IN	B-PP
O	525	533	research	research	NN	B-NP
O	534	538	into	into	IN	B-PP
O	539	549	carcinogen	carcinogen	NN	B-NP
O	550	557	adducts	adduct	NNS	I-NP
O	558	560	in	in	IN	B-PP
O	561	567	humans	human	NNS	B-NP
O	567	568	,	,	,	O
O	569	578	continued	continue	VBN	B-NP
O	579	591	improvements	improvement	NNS	I-NP
O	592	594	in	in	IN	B-PP
O	595	598	the	the	DT	B-NP
O	599	614	reproducibility	reproducibility	NN	I-NP
O	615	618	and	and	CC	I-NP
O	619	630	specificity	specificity	NN	I-NP
O	631	633	of	of	IN	B-PP
O	634	640	assays	assay	NNS	B-NP
O	641	644	for	for	IN	B-PP
O	645	648	DNA	DNA	NN	B-NP
O	649	656	adducts	adduct	NNS	I-NP
O	657	661	will	will	MD	B-VP
O	662	664	be	be	VB	I-VP
O	665	671	needed	need	VBN	I-VP
O	671	672	.	.	.	O

O	673	680	Perhaps	Perhaps	RB	B-ADVP
O	681	684	the	the	DT	B-NP
O	685	695	increasing	increase	VBG	I-NP
O	696	699	use	use	NN	I-NP
O	700	702	of	of	IN	B-PP
O	703	709	hybrid	hybrid	JJ	B-NP
O	710	723	methodologies	methodology	NNS	I-NP
O	724	726	to	to	TO	B-VP
O	727	738	concentrate	concentrate	VB	I-VP
O	739	746	adducts	adduct	NNS	B-NP
O	747	755	followed	follow	VBN	B-VP
O	756	758	by	by	IN	B-PP
O	759	767	specific	specific	JJ	B-NP
O	768	776	chemical	chemical	NN	I-NP
O	777	785	analyses	analysis	NNS	I-NP
O	786	790	will	will	MD	B-VP
O	791	796	allow	allow	VB	I-VP
O	797	801	such	such	JJ	B-NP
O	802	809	adducts	adduct	NNS	I-NP
O	810	812	to	to	TO	B-VP
O	813	815	be	be	VB	I-VP
O	816	825	monitored	monitor	VBN	I-VP
O	826	830	more	more	RBR	B-ADVP
O	831	840	precisely	precisely	RB	I-ADVP
O	840	841	.	.	.	O

O	842	844	Of	Of	IN	B-PP
O	845	851	course	course	NN	B-NP
O	851	852	,	,	,	O
O	853	860	further	further	JJ	B-NP
O	861	866	basic	basic	JJ	I-NP
O	867	875	research	research	NN	I-NP
O	876	880	into	into	IN	B-PP
O	881	884	the	the	DT	B-NP
O	885	895	mechanisms	mechanism	NNS	I-NP
O	896	898	of	of	IN	B-PP
O	899	913	carcinogenesis	carcinogenesis	NN	B-NP
O	914	918	will	will	MD	B-VP
O	919	924	allow	allow	VB	I-VP
O	925	928	the	the	DT	B-NP
O	929	940	measurement	measurement	NN	I-NP
O	941	943	of	of	IN	B-PP
O	944	952	specific	specific	JJ	B-NP
O	953	958	novel	novel	JJ	I-NP
O	959	966	markers	marker	NNS	I-NP
O	967	972	which	which	WDT	B-NP
O	973	976	are	be	VBP	B-VP
O	977	981	more	more	RBR	I-VP
O	982	989	closely	closely	RB	I-VP
O	990	994	tied	tie	VBN	I-VP
O	995	997	to	to	TO	B-PP
O	998	1001	the	the	DT	B-NP
O	1002	1009	disease	disease	NN	I-NP
O	1010	1018	endpoint	endpoint	NN	I-NP
O	1019	1023	than	than	IN	B-PP
O	1024	1031	adducts	adduct	NNS	B-NP
O	1031	1032	.	.	.	O

O	1033	1036	The	The	DT	B-NP
O	1037	1048	development	development	NN	I-NP
O	1049	1051	of	of	IN	B-PP
O	1052	1055	new	new	JJ	B-NP
O	1056	1062	assays	assay	NNS	I-NP
O	1063	1066	for	for	IN	B-PP
O	1067	1078	determining	determine	VBG	B-VP
O	1079	1088	metabolic	metabolic	JJ	B-NP
O	1089	1099	phenotypes	phenotype	NNS	I-NP
O	1100	1103	and	and	CC	I-NP
O	1104	1113	genotypes	genotype	NNS	I-NP
O	1114	1122	relevant	relevant	JJ	B-ADJP
O	1123	1125	to	to	TO	B-PP
O	1126	1140	carcinogenesis	carcinogenesis	NN	B-NP
O	1141	1147	should	should	MD	B-VP
O	1148	1155	improve	improve	VB	I-VP
O	1156	1159	our	our	PRP$	B-NP
O	1160	1169	estimates	estimate	NNS	I-NP
O	1170	1172	of	of	IN	B-PP
O	1173	1187	susceptibility	susceptibility	NN	B-NP
O	1188	1189	(	(	(	O
O	1189	1191	46	46	CD	B-NP
O	1191	1192	-	-	HYPH	O
O	1192	1194	48	48	CD	B-NP
O	1194	1195	)	)	)	O
O	1195	1196	.	.	.	O

O	1197	1201	Such	Such	JJ	B-NP
O	1202	1205	new	new	JJ	I-NP
O	1206	1216	approaches	approach	NNS	I-NP
O	1217	1222	along	along	IN	B-PP
O	1223	1227	with	with	IN	B-PP
O	1228	1231	the	the	DT	B-NP
O	1232	1241	sustained	sustained	JJ	I-NP
O	1242	1253	improvement	improvement	NN	I-NP
O	1254	1256	of	of	IN	B-PP
O	1257	1264	current	current	JJ	B-NP
O	1265	1271	assays	assay	NNS	I-NP
O	1272	1276	will	will	MD	B-VP
O	1277	1282	allow	allow	VB	I-VP
O	1283	1292	molecular	molecular	JJ	B-NP
O	1293	1303	approaches	approach	NNS	I-NP
O	1304	1306	to	to	TO	B-VP
O	1307	1315	continue	continue	VB	I-VP
O	1316	1318	to	to	TO	I-VP
O	1319	1325	enrich	enrich	VB	I-VP
B-Cancer	1326	1332	cancer	cancer	NN	B-NP
O	1333	1345	epidemiology	epidemiology	NN	I-NP
O	1346	1348	in	in	IN	B-PP
O	1349	1352	the	the	DT	B-NP
O	1353	1359	future	future	NN	I-NP
O	1359	1360	.	.	.	O

